Johnson & Johnson expects to have clear information on how efficient it’s by the tip of this month or early February, the US healthcare firm’s chief scientific officer stated.
Dr Paul Stoffels in an interview on Tuesday additionally stated J&J expects to fulfill its said goal of delivering 1 billion doses of its vaccine by the tip of this yr as the corporate ramps up manufacturing.
Dr Stoffels stated it was untimely to say what number of doses could be obtainable in March, presuming the corporate receives emergency authorization from the US Meals and Drug Administration.
The New York Instances reported earlier that J&J was experiencing manufacturing delays that would scale back the variety of doses available initially.
“We’re aiming for 1 billion doses in 2021. If it’s a
single dose, which means 1 billion folks. However will probably be in a ramp-up all year long,” Dr Stoffels stated.
Johnson & Johnson’s vaccine is being produced in america, Europe, South Africa and India with the assistance of contract producers with the intention to construct capability.
“It is a couple of weeks too early to be giving last numbers on what we are able to launch within the first couple months,” he stated.
Moncef Slaoui, chief adviser for the US Operation Warp Pace vaccine improvement program, stated the vaccine might present efficacy at or above 80%.
That may be under the efficacy of about 95% achieved in trials of already licensed vaccines from Pfizer Inc with BioNTech SE and Moderna Inc, however properly above the 50% benchmark for approval set by regulators.
It additionally has the benefit of being a single-shot vaccine, which implies it may defend extra folks quicker, and with out the chilly storage necessities of the opposite vaccines.
Dr Stoffels stated the corporate set an efficacy goal at 60%, however internally has been capturing for at the least 70% to 80%.
“We’re very assured that the vaccine will likely be a lot increased than 60%,” he stated, including that the “goal is for the best ranges, hopefully closing in on what Moderna and Pfizer are doing.”
Interim outcomes from the corporate’s Section I/II examine,
revealed on Wednesday within the New England Journal of Drugs, have helped increase that confidence.
The examine confirmed that 90% of 805 volunteers aged 18 to 55 developed protecting antibodies 29 days after a single dose, and that elevated to 100% by day 57.
The examine is ongoing, however the safety has lasted 71 days to this point.
Related information in individuals over age 65 will likely be obtainable in late January.